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“Three billion bases of sequence can be put on a single compact
disk (CD), and one will be able to pull a CD out of one’s pocket
and say, ‘Here is a human being; it’s me!’”
Walter Gilbert in Vision of the Grail1
“It’s been a growing conviction of mine that biologists have a
whole other way of talking to each other in the lab than they do
to the public.”
Evelyn Fox Keller2
I. INTRODUCTION ................................................................. 159
II. HISTORY OF THE GENE CONCEPT .............................. 162
A. UNIT OF HEREDITY ............................................... 162
B. GENE AS PARTICLE ............................................... 163
C. GENE AS SEQUENCE............................................. 164
D. GENE AS INFORMATION ...................................... 167
 2010 Andrew W. Torrance.
* Andrew W. Torrance is an Associate Professor at the University of Kansas
School of Law and a Research Associate at the Biodiversity Institute at the
University of Kansas. He received his Ph.D. in biology from Harvard University and his J.D. from Harvard Law School. The author would like to thank his
research assistants, Justin Hendrix, Jonathan Grossman, and Alison Dunehoo
for their invaluable assistance. He would also like to thank Christopher Kelty,
Visiting Professor of the History of Science, Harvard University, for his guidance in locating the best information about the history and sociology of the
gene concept, and Profs. Mark Lemley and Pamela Samuelson for their excellent comments, and for their invitation to participate in the inaugural STS &
IP Law Conference in Saint Helena, CA., May 8-10, 2008, sponsored by Stanford Law School and Berkeley Law School. This article was presented at the
STS & IP Law Conference.
1. Walter Gilbert, Vision of the Grail, in THE CODE OF CODES 96 *Daniel
J. Kevles and Leroy Hood eds., 1992).
2. Andrew Brown, Fox Among the Lab Rats, THE GUARDIAN, Nov. 4,
2000,
available
at
6,
http://www.guardian.co.uk/books/2000/nov/04/books.guardianreview6 (quoting
Evelyn Fox Keller).

157

TORRANCE LF CHECK.WEB (DO NOT DELETE)

158

MINN. J. L. SCI. & TECH.

3/9/2010 11:47 AM

[Vol. 11:1

E. GENE AS PROGRAM ............................................... 169
F. THE GENE CONCEPT UNRAVELS ....................... 170
III. GENE PATENTS .............................................................. 175
A. RECOMBINANT DNA ............................................. 175
B. PATENTS ON GENES ............................................. 176
C. GENES IN PATENTS .............................................. 178
IV. GENE TALK ...................................................................... 181
A. THE BIOTECHNOLOGY INDUSTRY .................... 181
B. THE RISE OF GENE TALK .................................... 182
C. GENE TALK AND GENE PATENTS ...................... 184
V. CONCLUSION .................................................................... 190
Since the existence of a discrete unit of heredity was first
proposed by Gregor Mendel, scientific concepts of the “gene”
have undergone rapid evolution. Beyond obvious epistemic and
operational importance to the scientific community, changing
gene concepts have exerted strong effects on institutions such
as medicine, the biotechnology industry, politics, and the law. A
particularly rich example of this is the interplay between gene
concepts and patent law. Over the last century, biology has elaborated gene concepts that variously emphasized genes as discretely material, genes as information, and genes as extremely
complex. By contrast, patent law has steadily adhered to a
simpler, more stable concept of the gene since the advent of
gene patents in the late 1970s. In fact, while the biology community3 has increasingly engaged in vigorous internal debate
regarding the gene’s complexity and uncertainty, it has tended
simultaneously to emphasize the simplicity and certainty of the
gene to constituencies outside the biology community, most
notably the United States Patent and Trademark Office
(USPTO) and the Federal courts. Rather than allow gene concepts to become contested by constituencies outside biology, the
biology community appears to have used its authority to maintain a portrayal of the gene that facilitates the appropriation of
rents from genes through the patent system. This use of “gene
talk” has undergirded the growth of biotechnology into a powerful industry that has economically rewarded investors, academic institutions, and biologists. Not only may gene talk have facilitated the patenting of genes, but the prominence of gene
patents describing a relatively simpler gene concept may have

3. “Biology community” is used hereafter to describe the professional biologists, whether in academia, biotechnology, or the government.
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fed back into biological science to promote a simpler, and more
patentable, concept of the gene even among members of the biology community.
I. INTRODUCTION
The concept of the “gene” has undergone tremendous transformation over the course of the last century. It began its life as
a hypothetical mechanism for transferring characters4 from one
generation to the next. A flurry of experimentation by Morgan
and other early “classical” geneticists, whose results revealed a
satisfying predictability to the inheritance of characters, caused
the inchoate and hypothetical gene to coalesce into a unit possessing substantiality and materiality.5 The materiality of the
gene was grounded even more firmly by the discovery that
genes were made of a specific chemical, that is, deoxyribonucleic acid (“DNA”). The discovery of the double-helical structure of
DNA by James Watson and Francis Crick, along with the implications of the double helix structure for the existence of a
“genetic code,” represented the high-water mark of the material
gene.6
The breaking of the genetic code suggested a new characteristic of the gene: information. Genes were portrayed as carrying information encoded by their constituent nucleotides.7 In
fact, the characterization of the operon8 by Jacob and Monod
suggested that the information carried by genes was not simply
information, but programmatic in nature.9 Similar to computer
software, the information encoded by a gene was viewed as operating like an algorithm, instructing the chemical machinery
of the cell to make structures and perform functions in particular orders with specific effects.
4. The term “character” is herein used in its taxonomic sense to denote
any characteristic or feature of an organism, including those characteristics or
features related to morphology, physiology, and behavior.
5. See discussion infra Part II.B.
6. See discussion infra Part II.C.
7. See discussion infra Part II.D.
8. BENJAMIN LEWIN, GENES IX 858 (2008) (“An operon is a unit of bacterial gene expression and regulation, including structural genes and control
elements in DNA recognized by regulator gene product(s).”); EVELYN FOX
KELLER, THE CENTURY OF THE GENE 57 (2000) (The word “operon” denotes “a
linked cluster of regulatory elements and structural genes whose expression is
coordinated by the product of a regulator gene situated elsewhere in the genome.”)
9. See discussion infra Part II.E.
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Methods of determining the specific nucleotides located on
particular genes developed substantially in the 1970s with the
invention of relatively rapid DNA sequencing technologies.10
The ability to sequence genes rapidly created a flood of DNA
sequence data. Meanwhile, recombinant DNA technology allowed genes and gene fragments to be excised from one location
in a genome, and then spliced into a different genomic location,
either in the same or a different individual organism, or even in
a different type of organism.11 Gene concepts emphasizing particulate materiality, information content, or encoded algorithmic programs, coupled with DNA sequencing and recombinant
DNA technologies, facilitated a view among biologists, and others, that one could “invent” DNA-based innovations just as one
could write software to run on a computer.12 Newly-sequenced
genes, as long as they had been isolated and purified, could now
be conceived of as inventions ripe for patent protection.13 After
the landmark decision in Diamond v. Chakrabarty, the United
States Patent and Trademark Office (USPTO) began regularly
to issue patents claiming sequenced genes.14
Just prior to the issuance of the first gene patent in 1981,
the simple linearity of the prevailing gene concept was fatally
challenged by the discovery that eukaryotic polypeptides
tended to be encoded by physically separate and noncontiguous
stretches of DNA. Many genes, rather than consisting of simple, contiguous linear arrays of nucleotides, like beads strung
together on a necklace, more accurately resembled fragments of
beads (“exons”) dispersed throughout a necklace, and separated
by non-gene-related sequences of nucleotides (“introns”).15
However, to a large degree, biologists do not acknowledge the
growing complexity of the gene concept when claiming genes in
patents (hereinafter “gene patents”). USPTO regulations and
judicial opinions, as they relate to gene patents, do not reflect
this complexity either.16 In fact, neither gene patents nor judicial opinions considering gene patents tend even to consider
gene concepts or definitions.
Meanwhile, debates about what a “gene” really is have
10.
11.
12.
13.
14.
15.
16.

See discussion infra Part II.F.
See discussion infra Part II.C.
See discussion infra Part II.F.
See discussion infra Part III.B.
See discussion infra Part III.B.
See discussion infra Part II.F.
See discussion infra Part III.B.
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raged within the biology community. Since the first gene patents issued early in the 1980s, the gene concept has decayed
towards incoherence. Evidence that genes may not only possess
introns and exons, but that they sometimes overlap each other,
encode products in multiple reading frames, and even encode
products in both directions, has led many biologists, including
some very prominent in the field, to conclude that the very idea
of a “gene” is no longer useful.17 In the meantime, patenting
genes has become routine for geneticists in both industry and
academia. Encouraged by the Bayh-Dole Act, universities have
become fertile sources of gene patents, and have thereby earned
vast sums of money from licensing these gene patents to the
biotechnology industry. The biotechnology industry itself, much
of whose market value is undergirded by gene patents rather
than actual commercial products, has also contributed to the
flood of gene patent applications.18
Growing incoherence in the biological understanding of
what a gene might be, and of what gene concept can best reflect
the empirical evidence, would seem to threaten the continued
availability of patents claiming genes. After all, the disclosure
requirements of patent law preclude the patenting of any invention that cannot be adequately and accurately described.19
Yet, gene patents tend to include minimal disclosure defining
what genes are or describing claimed genes beyond recitation of
their DNA sequences and putative utilities.20 Gene patents certainly do not teach the controversy surrounding gene concepts.
This raises the question of whether patent applications that
claim genes or gene-related inventions, but whose specifications oversimplify or simply ignore gene definitions, should issue as patents.
This article argues that the rhetorical portrayal of genes as
relatively simple and predictable entities can explain, at least
in part, the failure of gene patents or judicial opinions about
gene patents to reflect the controversy and complexity of the
biological understanding of genes. Evelyn Fox Keller coined the
phrase “gene talk” to describe the rhetorical practices of conversing about genes both among biologists and between biologists and non-biologists. Gene talk may be employed in re-

17.
18.
19.
20.

See discussion infra Part III.C.
See discussion infra Part VI.A.
35 U.S.C. §112, para 1 (2008).
See discussion infra Part II.B.

TORRANCE LF CHECK.WEB (DO NOT DELETE)

162

3/9/2010 11:47 AM

MINN. J. L. SCI. & TECH.

[Vol. 11:1

sponse to cultural, institutional, and economic imperatives that
create strong incentives to justify property (that is, patent)
rights in genes.21 Gene talk provides a useful shorthand for discussing a scientific concept whose meaning inspires tremendous disagreement among biologists; by using the word “gene”
loosely and contextually as a conceptual placeholder, biologists
have been able to elucidate much about genetics. However, the
biology community has also used gene talk successfully to foster enthusiasm, respect, and trust outside the biology community for the power and potential of genes without communicating the prodigious scientific uncertainty that surrounds the
structure, function, and even the existence of genes. Gene talk
in the context of gene patents could even influence gene concepts internal to the biology community.
II. HISTORY OF THE GENE CONCEPT
A. UNIT OF HEREDITY
The Origin of Species by Means of Natural Selection revolutionized biology by suggesting not only that lineages of organisms change their characters over time (that is, they evolve) but
by offering a causal mechanism for these changes (that is, natural selection).22 Nevertheless, Darwin left a significant question unanswered: what hereditary unit is associated with the
characters of organisms? Although he did suggest that a “gemmule” might be a unit of “pangenesis,” Darwin left to others the
task of elaborating a coherent concept of a unit of heredity.
Darwin never even knew the word “gene” because it was not
coined until more than twenty years after his 1882 death.
It took Gregor Mendel, an Augustinian monk who worked
contemporaneously with Darwin, to elucidate the fundamental
system of genetic inheritance. Mendel imagined a unit of heredity that he called the “Elemente.”23 Though his discoveries
would later form one of the bases of modern genetics, the contrast between the public reception of Mendel’s ideas and Darwin’s is remarkable: On the Origin of Species by Means of Natural Selection attracted immediate international attention,
while Mendel’s research remained obscure until translated

21. See EVELYN FOX KELLER, THE CENTURY OF THE GENE 10 (2000).
22. See generally CHARLES DARWIN, ON THE ORIGIN OF SPECIES BY MEANS
OF NATURAL SELECTION (1859).
23. See KELLER, supra note 21, at 19.
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from the original German and published in English in 1901.24
Soon after this rediscovery of Mendel’s research, Wilhelm Johannsen provided a name for the fundamental unit of heredity,
the “gene,” a term he derived from the last syllable of Hugo de
Vries’s “pangens.”25
Biologists quickly adopted the concept of the “gene” as the
unit of heredity, in part because it offered a solution to the
problem of how many observable traits appeared to pass from
generation to generation unchanged. “[T]he problem of trait
stability was answered by assuming the existence of an inherently stable, potentially immortal, unit that could be transferred intact through the generations.”26 This unit was the
gene.
B. GENE AS PARTICLE
Long before Mendel’s research became widely known, and
before the term “gene” had been coined, August Weismann had
predicted several characteristics of the unit of heredity. As Keller explained:
Whatever the mechanism by which a single cell reproduces the traits
of the parent, Weismann assumed the existence of particulate, selfreproducing elements that “determine” the properties of an organism;
appropriately enough, he called these elements determinants. This
assumption was hardly unique to Weismann—in fact, Darwin himself
had hypothesized the existence of some such elements (his gemmules).27

According to Weismann, determinants (that is, genes) were
not inchoate, but, rather, possessed discrete materiality. Specifically, his determinants were of “a definite chemical, and above
all, molecular composition.”28 A contemporary, Hugo de Vries
echoed Weismann’s materiality hypothesis, explaining that
“[j]ust as physics and chemistry go back to molecules and
atoms, the biological sciences have to penetrate to these units
in order to explain, by their combinations, the phenomena of

24. See generally Gregor Mendel, Experiments in Plant Hybridisation, 26
J. ROYAL HORTICULTURAL SOC’Y 1 (1901) (proving that certain pairs of differentiating characters, the germ-cells of a hybrid, or cross-bred, are pure, being
carriers and transmitters of either the one character or the other, not both).
25. KELLER, supra note 21, at 1–2.
26. Id. at 14.
27. KELLER, supra note 21, at 16.
28. August Weismann, The Continuity of the Germ-Plasm as the Foundation of a Theory of Heredity, in ESSAYS UPON HEREDITY AND KINDRED
BIOLOGICAL PROBLEMS 161, 168 (Edward B. Poulton et al. eds., 1889).
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the living world.”29
Thomas Hunt Morgan was the first great experimental geneticist since Mendel. In his “Fly Room” at Columbia University, Morgan established the fruit fly, Drosophila melanogaster,
as the experimental organism of choice for studying genetics,
and empirically that genes were located on chromosomes.30 By
the time Morgan became the first geneticist to receive the Nobel Prize in Medicine, in 1933, in part due to the work of his laboratory and alumni thereof, the majority of other geneticists
had come to believe that “genes . . . [were] incontrovertibly real,
material entities—the biological analogue of the molecules and
atoms of physical science . . . .”31 Morgan suggested in his 1926
book, The Theory of the Gene, that genes on chromosomes were
“like beads on a string.”32 Morgan’s analogy to jewelry assumed
significant influence over time, and “genes became generally
viewed as discrete, stable, independently segregating units of
inheritance lined up along a chromosome.”33
C. GENE AS SEQUENCE
By the 1940s, the particulate theory of genes as discrete,
physical structures on chromosomes had been widely accepted
among geneticists. The gene’s structure and function was also
assumed to be linked to the genes’ causal effects:
Throughout the history of both classical and early molecular genetics,
the gene was generally assumed to be not only a fixed and unitary locus of structure and function but also a locus of causal agency. T.H.
Morgan, for example, regarded the idea that genes are the causal
agents of development as so basic and so self-evident that an understanding of heredity did not require its elaboration.34

However, lacking specific knowledge of gene structure, geneticists were limited in understanding both gene function and
causal agency.
In 1943, Avery, McLeod, and McCarty identified “DNA as
the carrier of biological specificity in bacteria.” 35 They proposed
29. HUGO DE VRIES, INTRACELLULAR PANGENESIS 13 (C. Stuart Gager
trans., The Open Court Publishing Co. 1910) (1889).
30. See JAMES D. WATSON ET AL., MOLECULAR BIOLOGY OF THE GENE 12–
13 (Beth Wilbur et al. eds., 6th ed. 2008).
31. KELLER, supra note 21, at 2.
32. THOMAS HUNT MORGAN, THE THEORY OF THE GENE 24 (1926).
33. Leonie Moyle, Most Ingenious: Troubles and Triumphs of the Century
of Genes, 17 BIOLOGY AND PHIL. 715, 715–16 (2002).
34. KELLER, supra note 21, at 46.
35. Id. at 3.
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that DNA “must be regarded not merely as structurally important but as functionally active in determining the biochemical
activities and specific characteristics of pneumococcal cells.”36
Their conclusions were confirmed by Hershey and Chase in
their 1952 “blender” experiment, which used radiolabeled amino acids and nucleotides to detect whether proteins or nucleic
acids were the carriers of heredity.37
One year later, one of the greatest scientific advances in
genetics allowed gene structure, function, and causal agency to
be linked together intimately: elucidation of the double-helical
structure of DNA. “[I]t was the triumphal announcement by
James D. Watson and Francis Crick in 1953 which convinced
biologists not only that genes are real molecules but also that
they are constituted of nothing more mysterious than deoxyribonucleic acid.”38 As Keller relates,
[n]ot only did that structure provide a mechanism for the gene’s remarkable capacity for self-replication—a mechanism that was stunning in its very simplicity—but also, and at the same time, it provided
an (equally simple) explanation for the stability of the gene—for the
ostensibly miraculous fidelity with which it could be copied over so
many generations. Complementary base-pairing could, at one fell
swoop, do the work of both replication and conservation. . . . [A]n actual chemical substance—one already known to be a basic constituent
of chromosomes—had been shown to have the necessary defining
properties. Even before a mechanism was worked out by which the
sequence of nucleotides in a DNA molecule could be translated into a
sequence of amino acids in a protein molecule, confidence was widespread that the material basis of genetics had finally been established.39

Watson and Crick demonstrated that:
In the double helix, the two DNA chains are held together by hydrogen bonds . . . between pairs of bases on the opposing strands . . . .
This base pairing is very specific: the purine adenine only base-pairs
to the pyrimidine thymine, whereas the purine guanine only basepairs to the pyrimidine cytosine. In double-helical DNA, the number
of A residues must be equal to the number of T residues, whereas the
number of G and C residues must likewise be equal . . . . As a result,
the sequence of the bases of the two chains of a given double helix
have a complementary relationship, and the sequence of any DNA

36. Oswald T. Avery et al., Studies on the Chemical Nature of the Substance Inducing Transformation of Pneumococcal Types, 79 J. EXPERIMENTAL
MED. 137, 155 (1944).
37. A. D. Hershey and Martha Chase, Independent Functions of Viral Proteins and Nucleic Acid in Growth of Bacteriophage, 36 J. GEN. PHYSIOLOGY 39
(1952).
38. KELLER, supra note 21, at 3.
39. Id. at 23–25.
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strand exactly defines that of its partner strand.40

Studying the rII gene of the T4 bacteriophage, Seymour
Benzer went beyond the discoveries of Watson and Crick, and
“provided the crucial genetic evidence for the linearity of the internal structure of genes.”41
Thus, the general materiality of the gene was complemented by the additional conception of the gene as composed of
a linear molecule comprised of a specific sequence of four deoxyribonucleotides. In the less than fifty years that had passed
since the word “gene” had been coined, the gene concept now
included molecular materiality and a highly specific structure.
This definitively physical concept allowed “the gene to become
the foundational concept capable of unifying all of biology.”42
Since the 1970s, it has been possible to determine the precise ordered sequence of nucleotides in a particular stretch of
deoxyribonucleic acid of any type of organism, from eubacteria
and archaea to plants and animals. Recombinant DNA technology, by providing biologists with the ability to cut apart a DNA
sequence at a specified locus, facilitated early sequencing efforts.43 However, it was a pair of new sequencing techniques in
the 1970’s that allowed DNA sequencing to commence on a
grand scale. Almost simultaneously, two research groups developed methods by which one could determine the precise nucleotide sequence of a fragment of DNA nucleotide base-pair by
nucleotide base-pair. Both methods shared the same general
approach:
The underlying principle of DNA sequencing is based on the separation, by size, of nested sets of DNA molecules. Each of the DNA molecules starts at a common 5’ end, and terminates at one of several alternative 3’ endpoints. Members of any given set have a particular
type of base at their 3’ ends. Thus, for one set, the molecules all end
with a G, for another a C, for a third an A, and for the final set a T.
Molecules within a given set (e.g., the G set) vary in length depending
on where the particular G at their 3’ end lies in the sequence. Each
fragment from this set therefore indicates where there is a G in the
DNA molecule from which they were generated.44

One group, led by Walter Gilbert and Allan Maxam, invented a method of DNA sequencing later named “Maxam-

40.
41.
42.
43.
44.

WATSON ET AL., supra note 30, at 22.
KELLER, supra note 21, at 52.
Id. at 3.
GRIFFITHS ET AL., INTRODUCTION TO GENETIC ANALYSIS 343-60 (2005).
WATSON ET AL., supra note 30, at 753.
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Gilbert sequencing.”45 Maxam-Gilbert sequencing is based on
radioactively labeling DNA molecules at their 5’ termini and
then subjecting them “to four different regimens of chemical
treatment that cause them to break preferentially at Gs, Cs,
Ts, or As.”46 The other group, led by Frederick Sanger, developed the “chain-termination” method.47 In chain-termination
sequencing, DNA polymerase is used to make a new copy of
DNA from an existing DNA template, and modified 2’-,3’- dideoxynucleotides (ddNTPs) are incorporated into the new copy
of DNA by DNA polymerase, preventing further elongation of
the strand.48
Gilbert and Sanger won the 1980 Nobel Prize in Chemistry
“for their contributions concerning the determination of base
sequences in nucleic acids.”49 Their methods of relatively rapid
DNA sequencing spurred a rapid increase in the determination
of the specific DNA sequences of many organisms, including
humans. Rapid advancements in PCR, automated sequencers,
and bioinformatics would later turn this rise into a flood, ultimately leading to the sequencing of entire genomes.50
D. GENE AS INFORMATION
As the material gene concept reached its apotheosis with
the elucidation of the double helical structure of DNA, a quite
different concept of the gene—as information—was simultaneously growing in importance among biologists. Early in the
Twentieth Century, Archibald Garrod had proposed that “genes
work by controlling the synthesis of specific enzymes.”51 In the
early 1940s, George Beadle and Edward Tatum “used the fungus Neurospora as a probe into the gene. Linking biochemical
methods with the techniques of Mendelian genetics, the two researchers demonstrated that one gene controlled a single chemical reaction, which in turn was regulated by a specific en45. See Allan M. Maxam and Walter Gilbert, A New Method for Sequencing DNA, 74 PROC. NAT’L ACAD. SCI. U.S. 560 (1977).
46. WATSON ET AL., supra note 30, at 754.
47. See F. Sanger et al., DNA Sequencing with Chain-Terminating Inhibitors, 74 PROC. NAT’L ACAD. SCI. U.S. 5463 (1977).
48. WATSON ET AL., supra note 30, at 754.
49. See Bo G. Malmstrom, Professor, Royal Academy of Sciences (1980), in
NOBEL LECTURES: CHEMISTRY 377-432 (1980).
50. See, e.g., J. Craig Venter et al., The Sequence of the Human Genome,
291 SCIENCE 1304 (2001); E. S. Lander et al., Initial Sequencing and Analysis
of the Human Genome, 409 NATURE 860 (2001).
51. WATSON ET AL., supra note 30, at 19.
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zyme . . . .”52
By specifically linking the action of a single gene to the action of a single enzyme, Beadle and Tatum confirmed Garrod’s
“One Gene-One Enzyme Hypothesis.”53 Since all of the enzymes
known at that time were proteins, “the key problem was the
way genes participate in the synthesis of proteins.”54 Although
there were numerous possible explanations for this phenomenon, “[f]rom the very start of serious speculation, the simplest
hypothesis was that genetic information within genes determines the order of the 20 different amino acids within the polypeptide chains of proteins.”55
Soon after their discovery of the double helical structure of
DNA, Watson and Crick were able to make informational inferences from the double helix. As Keller relates:
Watson and Crick published a second paper—on “Genetical Implications of the Structure of Deoxyribonucleic Acid”—whose main point
was to argue that the structure of DNA show us [the mechanism by
which DNA duplicates itself] . . . . Within such a framework, the one
gene-one enzyme hypothesis took on a new kind of sense. Now it could
be understood as suggesting a direct correspondence between the sequence of nucleotides in a gene and the sequence of amino acids in a
protein . . . .56

The information encoded by the sequence of deoxyribonucleotides in a strand of DNA could be used to specify the synthesis of a corresponding sequence of amino acids, yielding a protein.
In 1957, Francis Crick proposed the “sequence hypothesis.”57 “In its simplest form [Crick’s hypothesis] assumes that
the specificity of a piece of nucleic acid is expressed solely by
the sequence of its bases, and that this sequence is a (simple)
code for the amino acid sequence of a particular protein.”58 Although many additional details about protein synthesis are
now known, this basic principle of information transfer from
gene to protein is still considered sound.
Despite elucidation of the general mechanism by which genetic information translated into protein synthesis, the precise
52.
53.
54.
55.
56.
57.
58.

LILY E. KAY, WHO WROTE THE BOOK OF LIFE 52 (2000).
Id.
WATSON ET AL., supra note 30, at 19.
Id.
KELLER, supra note 21, at 51–52.
Id. at 52.
F. H. C. Crick, On Protein Synthesis, 12 SYMP. SOC’Y FOR
EXPERIMENTAL BIOLOGY 138, 152 (1958).
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code remained unknown. In the first definitive demonstration
that information from nucleic acids corresponds specifically to
protein sequence, Marshall Nirenberg and Heinrich Matthaei
“observed in 1961 that the addition of the synthetic polynucleotide poly U (UUUUU . . .) to a cell-free system capable of making proteins leads to the synthesis of polypeptide chains containing only the amino acid phenylalanine. The nucleotide
groups UUU thus must specify phenylalanine.”59
Over the next six years, Nirenberg, Matthaei, and other biologists raced to unravel all of the “words” in the “[genetic]
code.”60 Accelerated by “fierce competition” among numerous
research groups, “[b]y 1967 the [genetic] code was essentially
completed; its momentous significance captured by the many
scientific writings and media coverage which announced an impending revolution in biology, both its epic promises and its perils.”61
The influence of the “information gene concept” has retained its salience right up until the present time. In addition
to the widespread understanding of genes as material particles,
“[t]he human genome is now generally viewed as an information system and, more specifically, as a ‘Book of Life’ written in
the language of DNA, or DNA code, to be read and edited.”62
E. GENE AS PROGRAM
In an extension of the “information gene concept,” some biologists have suggested that genes are like programs that encode instructions that the cell must carry out. Even before the
genetic code had been cracked, Francis Crick remarked that
“DNA makes RNA, RNA makes protein, and proteins make
us.”63 François Jacob and Jacques Monod proposed that “the
genome contains not only a series of blue-prints, but a coordinated program of protein synthesis and the means of controlling its execution.”64 In late 1950s, Jacob and Monod had
discovered that some genes encoded products that regulated
the actions of other genes.65 They proposed the “operon model”
59. WATSON ET AL., supra note 30, at 37.
60. KAY, supra note 52, at 330.
61. Id.
62. Id. at 1.
63. KELLER, supra note 21, at 54.
64. François Jacob & Jacques Monod, Genetic Regulatory Mechanisms in
the Synthesis of Proteins, 3 J. MOLECULAR BIOLOGY 318, 354 (1961).
65. WATSON ET AL., supra note 30, at 561.
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to represent how such gene regulation might occur.66 The operon model spurred acceptance of the genetic program gene concept by providing a specific example of such a genetic program.
In his 1965 book, The Molecular Biology of Development,
James Bonner envisioned a comprehensive “genetic program”
to explain how genes built and maintained organisms.67 In this
book, Bonner described a “master programme constituted in
turn of a set of subprogrammes or subroutines.”68 He subdivided the subroutine even further into “a list of cellular instructions or commands.”69
Despite obvious similarities between computer programs
and genetic programs, the latter do appear to possess important differences from the former. In light of these differences,
computers cannot take sole credit for the notion of a genetic program.
Compelling as the analogy may be, equating the genetic material of
an egg with the magnetic tape of a computer does not imply that that
material encodes a program; it might, for example, just as well be
thought of as encoding data to be processed by a program located
elsewhere in the cell.70

However, the program gene concept has been influential in
suggesting that, just like computer software, a genetic program
can confer qualities of consistency and predictability on an organism.71 Furthermore, if genes can be conceived of as genetic
programs, then one may be able to “reprogram” organisms by
modifying their genes.
F. THE GENE CONCEPT UNRAVELS
The operon model proposed by Jacob and Monod significantly complicated the understanding of what genes are. No
longer did genes merely encode enzymes. They also encoded
regulatory products. These products include “repressors,” “operators,” “promoters,” “terminators,” “leaders,” and “activators,”
each playing specific roles in the regulation of gene expression.72 This represented a dire threat to the “One Gene-One
66. LEWIN, supra note 8.
67. See JAMES BONNER, THE MOLECULAR BIOLOGY OF DEVELOPMENT 6
(1965).
68. Id. at 134.
69. KELLER, supra note 21, at 85–86.
70. Id. at 81.
71. As discussed below, organisms, in fact, tend to exhibit much less consistency and predictability than the analogy with computer software would
suggest.
72. WATSON ET AL., supra note 30, at 394–97, 547–49.
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Enzyme Hypothesis.”
The DNA sequencing technologies developed in the 1970s
revealed eukaryotic genes to be radically different in structure
than had been assumed. Until the 1970s, most of the genes
with known specific nucleotide sequences were derived from
eubacteria or their viruses. For most of these organisms, “the
coding sequence is contiguous: the codon for one amino acid is
immediately adjacent to the codon for the next amino acid in
the polypeptide chain.”73 However, the accumulation of DNA
sequences from eukaryotic organisms demonstrated that eukaryotic genes almost always had more complex structures.74
By the late 1970s, Richard Roberts and Philip Sharp had
disproven the hypothesis that all genes were linear and continuous by demonstrating that quiescent, “nonexpressed” portions of DNA (that is, “introns”) were situated in the midst of
active, “expressed” portions of DNA (that is, “exons”) coding for
polypeptides.75 In other words, “[m]any of the genes that code
for proteins in higher organisms turn out not to be continuous
but fragmented . . . .”76 Because of “this alternating pattern of
exons and introns, genes bearing noncoding interruptions are
often said to be ‘in pieces’ or ‘split’.”77 Thus, genes in eukaryotes
depart significantly from earlier gene concepts that envisioned
simple, linear contiguity. Rather, “[t]he highly interrupted
structure of eukaryotic genes suggests a picture of the eukaryotic genome as a sea of introns (mostly but not exclusively
unique in sequence), in which islands of exons (sometimes very
short) are strung out in individual archipelagoes that represent
genes.”78
The existence of introns and exons destroyed the universal
applicability of the One Gene-One Enzyme Hypothesis. If genes
are not linear and contiguous in sequence structure, but instead fragmented,
there is no strict one-to-one correspondence between the sequence of a
gene and that of a protein it gives rise to. Thus the original RNA
transcript directly transcribed from the gene (the messenger RNA, or
mRNA) must be processed to remove these junk sequences before pro-

73.
74.
75.
76.
77.
78.

Id. at 415.
See id.
KELLER, supra note 21, at 59.
Id.
WATSON ET AL., supra note 30, at 415.
LEWIN, supra note 8, at 47.
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tein synthesis can begin.79

On average, a eukaryotic gene is split into four exons by
three introns.80 There exists great variability in the number of
introns a gene may have, “from one in the case of most introncontaining yeast genes (and a few human genes), to 50 in the
case of the chicken proα2 collagen gene, to as many as 363 in
the case of the Titin gene of humans.”81
Even genes divided by introns tend to be “transcribed into
a single RNA copy of the entire gene.”82 Because “the proteinsynthesizing machinery of the cell . . . is equipped only to translate mRNAs containing a contiguous stretch of codons,”83 the
introns present in the initially transcribed “pre-mRNA” are further processed by “RNA splicing.”84 The resulting mRNA is
then ready to be translated into a polypeptide.85 However, even
this scenario may be complicated further by “alternative splicing,” wherein “mRNAs containing different selections of exons
can be generated from a given pre-mRNA.”86 Through alternative splicing, “a gene can give rise to more than one polypeptide
product,” each of which alternative polypeptides are called “isoforms.”87 Isoforms are the rule rather than the exception: “[i]t is
estimated that up to 75% of the genes in the human genome
are spliced in alternative ways to generate more than one isoform.”88 Furthermore, the numbers of possible isoforms from
each individual gene can be staggering, ranging
from two to hundreds or even thousands. For example, the Slo gene
from rat, which encodes a potassium channel expressed in neurons,
has the potential to encode 500 alternative versions of that product.
And . . . one particular Drosophila gene can encode as many as 38,000
possible products as a result of alternative splicing.”89

Alternative splicing suggests a One Gene-Multiple Enzyme
Hypothesis.
There is even more complexity in genes beyond alternative
splicing. Genes may also overlap one another. This may occur
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.

KELLER, supra note 21, at 60.
WATSON ET AL., supra note 30, at 415.
Id. at 415–16.
Id. at 416.
Id. at 417.
See id.
See id.
Id.
Id.
Id.
Id.
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when “[t]he first half (or second half) of a gene is used independently to specify a protein that represents the first (or second)
half of the protein specified by the full gene.”90 Genes may also
overlap in a more subtle manner when the same sequence of DNA is
shared between two nonhomologous proteins. This situation arises
when the same sequence of DNA is translated in more than one reading frame. In cellular genes, a DNA sequence usually is read in only
one of the three potential reading frames. In some viral and mitochondrial genes, however, there is an overlap between two adjacent
genes that are read in different reading frames.91

Genes have been discovered contained within larger
genes,92 “nestled within the non-protein coding intron of another [gene],”93 and in “countless other weird arrangements.”94 Recent studies of “all the transcripts from ten chromosomes across
eight human cell lines” have yielded a view of genes and their
products characterized by “mind-boggling complexity.”
Instead of discrete genes dutifully mass-producing identical RNA
transcripts, a teeming mass of transcription converts many segments
of the genome into multiple RNA ribbons of differing lengths. These
ribbons can be generated from both strands of DNA, rather than just
one as was conventionally thought. Some of these transcripts come
from regions of DNA previously identified as holding protein-coding
genes. But many do not.95

In light of the evidence, a One Gene-Multiple Enzymes
Hypothesis might be inadequate to describe what a gene is.
Given the complexity discussed above, Benjamin Lewin, of
Harvard University, has suggested an inversion of the Hypothesis’ usual order; rather than One Gene-One Enzyme, he
suggests One Enzyme-One Gene.96
One of the leading genetics textbooks , GENES IX, by Benjamin Lewin summarizes the complexities that increasingly
call into question existing gene concepts in understated and
somewhat enigmatic fashion: “[t]he concept of the gene has
evolved significantly in the past several years. The question of
what’s in a name is especially appropriate for the gene.”97 The

90. LEWIN, supra note 8, at 45.
91. Id.
92. See Helen Pearson, What is a Gene?, 441 NATURE 399 (2006).
93. Id. at 401.
94. Id. at 399.
95. Id.
96. LEWIN, supra note 8, at 53 (using the most general term “polypeptide”
instead of “enzyme”: “Instead of saying ‘one gene-one polypeptide,’ we may describe the relationship as ‘one polypeptide-one gene.’”).
97. Id.
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name that has dominated discussions of units of heredity for a
century—”gene”—has achieved vast influence both within biology and in wider society. Yet, the scientific usefulness of the
word “gene” is now in doubt among those most familiar with
the evidence increasingly undermining the accuracy of gene
concepts. Almost one-hundred years ago, the man who coined
the term “gene,” Wilhelm Johannsen, justified his neologism by
expressing his anxieties about previous descriptions of hereditary units: “[i]t is a well established fact that language is not
only our servant, when we wish to express—or even to conceal—our thoughts, but that it may also be our master, overpowering us by means of the notions attached to the current
words.” 98
After a century, Johannsen’s “very applicable little word”99
may have graduated from servant to master and may now be
“overpowering us by means of the notions attached to [it].”100
One of the world’s preeminent geneticists, William Gelbart, has
written that the gene might be “[a] concept past its time . . . .
[U]nlike chromosomes, genes are not physical objects but are
merely concepts that have acquired a great deal of baggage
over the past decades.101 Though important in the development
of genetics “we may well have come to the point where the use
of the term ‘gene’ . . . might in fact be a hindrance to our understanding.”102
Though the scientific justification of the “gene” has begun
to wane, the power of what Keller terms “gene talk” has remained strong. For the purposes of this article, “gene talk” refers to the verbal invocation of the word “gene” or its attendant
concepts. As Keller has suggested, gene talk has played key
roles in the rise of biotechnology and the biotechnology industry.103 And, one of the ways in which gene talk has been highly
successful has been to secure property rights in genes through
the patent system despite declining scientific certainty about
what exactly a gene is.

98. W. Johannsen, The Genotype Conception of Heredity, 45 THE AM.
NATURALIST 129, 132 (1911).
99. Id.
100. Id.
101. William M. Gelbart, Databases in Genomic Research, 282 SCIENCE
659, 660 (1998).
102. Id.
103. KELLER, supra note 21, at 10.
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III. GENE PATENTS
A. RECOMBINANT DNA
In 1972, Dr. Ananda M. Chakrabarty, a staff biologist at
General Electric Company, filed U.S. patent application serial
number 05/260,563.104 This patent application claimed, among
other inventions, a “bacterium from the genus Pseudomonas
containing therein at least two stable energy-generating plasmids . . . .”105 In the wake of the watershed 1980 Supreme
Court decision in Diamond v. Chakrabarty, allowing the patenting of recombinant eubacteria,106 this patent application issued as United States Patent No. 4,259,444 (‘444 patent).107
The ‘444 patent, which involves non-genomic “plasmids” containing desired genes, 108 represents a key moment in the evolution of patentable subject matter.
Stanley Cohen and Herbert Boyer, molecular biologists at
Stanford University and the University of California San Francisco (“UCSF”), respectively, spent 1973 and 1974 developing a
method for transferring DNA from one type of organism into
the cells of a distinctly different type of organism.109 This
marked the birth of the “recombinant DNA” revolution in biology.110 In November of 1974, Stanford University and UCSF
filed parent patent application 520,691 that ultimately matured into patent application 06/001,021, claiming recombinant
DNA methods invented by Cohen and Boyer, and issued in
1980 by the USPTO as U.S. Patent Number 4,237,224 (‘224 patent);111 the ‘224 patent claimed only recombinant DNA methods, not DNA molecules or recombinant organisms themselves.112 By 1977, the human gene, somatostatin, had been
expressed within the eubacterium, Escherichia coli.113 Recom104. U.S Patent No. 4,259,444 (filed June 7, 1972).
105. Id. at col.16 l.23–25.
106. See Diamond v. Chakrabarty, 447 U.S. 303, 318 (1980).
107. ‘444 Patent.
108. See id.
109. Sally Smith Hughes, Making Dollars Out of DNA: The First Major Patent in Biotechnology and the Commercialization of Molecular Biology, 92 ISIS
541, 541 (2001).
110. Id. at 542.
111. Id.
112. U.S. Patent No. 4,237,224 col. 17 l.4–31(filed Jan. 4, 1979). Note that
all fourteen claims begin with the words “A method.”
113. See Keiichi Itakura et al., Expression in Escherischia coli of a Chemically Synthesized Gene for the Hormone Somatostatin, 198 SCIENCE 1056,
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binant DNA technology offered “a simple method for isolating
and amplifying any gene or DNA segment and moving it with
controlled precision, allowing analysis of gene structure and
function in simple and complex organisms.”114 When coupled
with the relatively rapid DNA sequencing methods developed
in the mid-1970s, modern biotechnology had been born.115
B. PATENTS ON GENES
As the 1970’s dawned, biologists, and the institutions that
employed them, began securing significant numbers of patents
claiming the complex organic molecules of life. In 1971, U.S.
Patent Numbers 3,607,370116 and 3,619,206117 issued, claiming
“polypeptide” and “protein” per se, respectively. Earlier, patents
had issued claiming methods involving polypeptides and proteins. In 1972, the first claim to a “peptide” per se appeared in
U.S. Patent Number 3,645,689.118 By 1973, “DNA” had been included as an element of a patented claim.119
The term “gene” first appeared as a claim element in U.S.
Patent No. 3,710,511.120 By 1978, U.S. Patent Number
4,116,770 had issued, and its claims 10, 11, and 12 were directed to phenotypic traits expressed by specific “genes.”121 Finally, in 1982 U.S. Patent No. 4,363,877 (“the ‘877 patent”) issued, and included independent claims 1 and 4, which were
directed to “recombinant DNA transfer vector[s]” comprising
specified nucleotide sequences of codons for “human chorionic
somatomammotropin” and “the growth hormone of an animal
species,” respectively.122 This was the first “gene” patent, claim-

1056–63 (1977).
114. Hughes, supra note 109, at 541.
115. See discussion supra Part II.F.
116. Entitled “Pressure-Sensitive Adhesive Tape Comprising Gluten Hydrolypate Derivatives.”
117. Entitled “Modified Proteins.”
118. See U.S. Patent No. 3,645,689 (filed Apr. 9, 1970) (Entitled “Method
and Apparatus for Analyzing Proteins”).
119. See U.S. Patent No. 3,755,086 (filed Feb. 9, 1971) (Entitled “Diagnostic
Method Utilizing Synthetic Deoxyrilionucleotide Oligomer Template”).
120. See U.S. Patent No. 3,710,511 (filed Apr. 21 1971) (Entitled “Procedures for Use of Genic Male Sterility in Production of Commercial Hybrid Maize”).
121. See U.S. Patent No. 4,116,770 (filed Feb. 27, 1975).
122. See U.S. Patent No. 4,363,877 (filed Apr. 19, 1978) (Entitled “Recombinant DNA Transfer Vectors”).
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ing genes per se.123 Although the claims of the ‘877 patent did
not specifically recite the word “gene,” the specification’s
“SUMMARY OF INVENTION” did identify “genes coding for
RGH, the major portion of HCS and the major portion of HGH,
respectively.”124 Oddly, this first gene patent largely failed to
define a gene. The closest the ’877 patent’s specification gets to
such a definition is the following passage: “isolating the mRNA
which contains the nucleotide sequence coding for the amino
acid sequence of a particular protein is equivalent to the isolation of the same sequence, or gene, from the DNA itself.”125 In
other words, the ‘877 patent equates a gene with the nucleotide
sequence of an mRNA transcript; by implication, a gene is
simply a nucleotide sequence that produces an mRNA.
Patents and patent applications claiming genes both increased rapidly after the Diamond v. Chakrabarty decision in
1980. Figure 1 shows annual patent application filings with
“gene” in at least one claim during the period from 1971 to
2007. Such filings rose from just above zero in 1977 to more
than 100 in 1984, more than 500 in 1993, almost 1000 in 1994,
to a peak of over 1600 filed in 1995 alone. While filings remained at least—or extremely close to—1000 per year from
1994 until 2002, thereafter filings of such patent applications
declined rapidly to well below 500 through 2007.126 By way of
comparison, Figure 1 also shows that annual patent filings
with “DNA” or “nucleotide sequence” in at least one claim follow the same trajectory as do those with “gene.”

123. Leslie Gladstone Restaino & Theresa Takeuchi, Gene Patents and
Global Competition Issues, 26 GENETIC ENGINEERING AND BIOTECHNOLOGY
NEWS 10, 10 (2006).
124. ‘877 Patent, at col.8 l.7–9.
125. Id. at col.5 l.35–40 (emphasis added).
126. These data includes a lag-time of approximately 18 months, reflecting
the rolling publication window of 18 months from earliest priority date.
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Figure 1. Claim Language in Patent Applications
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Figure 2 shows annual patent issuances with “gene” in at
least one claim during the period from 1971 to 2007. Such filings rose from just above zero in 1981 to more than 100 in
1988, more than 500 in 1996, more than 1300 in 1998, to a
peak of almost 1500 in 1999. From 1998 to 2007, patent issuances have remained above 1000 per year in all but two
years, and there has been only a relatively gradual decline in
issuances from the peak year of 1999. By way of comparison,
Figure 2 also shows that annual issuances of patents with
“DNA” in at least one claim follow the same trajectory as do
those with “gene.”
Figure 2. Claim Language in Issued Patents
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C. GENES IN PATENTS
Neither patents nor patent litigation tend to spend much

TORRANCE LF CHECK.WEB (DO NOT DELETE)

2010]

GENE CONCEPTS

3/9/2010 11:47 AM

179

effort attempting to define what a gene is.127 Although many
thousands of patent applications have employed the words
“gene” or “genes” within their claims, and a significant fraction
of these patent applications have issued as United States patents, seldom do patent applicants trouble themselves with defining these terms in their specifications. For example, of the
more than 15,000 issued U.S. patents that include the term
“gene” in their claims, only sixteen include the phrase “a gene
is defined as,” only seventeen include the phrase “genes are defined as,” only ten include the phrase “definition of a gene,” and
only four include the phrase “definition of genes.”128
Similarly, of a group of fifteen federal court opinions that
discuss gene definitions,129 only two, Amgen, Incorporated v.
Chugai Pharmaceutical Company, 130 and Carnegie Mellon
University v. Hoffman-La Roche Incorporated,131 actually provide a definition of a gene.132 However, the Amgen definition

127. A review of the first 500 search results of patents in “Google Patent
Search” reveals that only about 20% of the resulting patents attempt to define
“gene.” Almost all of these definitions are highly simplistic in nature, and none
of them seriously reflects the scientific complexity that has surrounded genes
over the last several decades.
128. These results are based on searches of these exact phrases in the
Google Patent Search database of all “Issued Patents” on April 9, 2008.
129. Monsanto Co. v. Bayer Bioscience N.V., 514 F.3d 1229, 1232 (Fed. Cir.
2008); Mycogen Plant Sci., Inc. v. Monsanto Co., 91 Fed. Appx. 666, 667 (Fed.
Cir. 2004); Genzyme Corp. v. Transkaryotic Therapies, Inc., 346 F.3d 1094,
1105 (Fed. Cir. 2003); Enzo Biochem, Inc. v. Gen-Probe Inc., 296 F.3d 1316
(Fed. Cir. 2002); Mycogen Plant Sci., Inc. v. Monsanto Co., 252 F.3d 1306,
1319 (Fed. Cir. 2001), vacated, 535 U.S. 1109 (2002); Hitzeman v. Rutter, 243
F.3d 1345, 1357 (Fed. Cir. 2001); In re Deuel, 51 F.3d 1552, 1558 (Fed. Cir.
1995); Amgen, Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1206 (Fed. Cir.
1991); In re Merat, 519 F.2d 1390, 1392 (C.C.P.A. 1975); Carnegie Mellon Univ. v. Hoffman-La Roche, Inc., No. C 95-3524 SI, No. C 01-0415 SI, 2007 U.S.
Dist. LEXIS 20386, at *8 (N.D. Cal. Mar. 22, 2007); Carnegie Mellon Univ. v.
Hoffman La Roche, Inc., 148 F. Supp. 2d 1004, 1013 (N.D. Cal. 2001), aff’d,
541 F.3d 1115 (Fed. Cir. 2008); E.I. Du Pont de Nemours & Co. v. Okuley, No.
C2-97-1205, 2000 U.S. Dist. LEXIS 21385, at *57 (S.D. Ohio Dec. 21, 2000),
aff’d, 344 F.3d 578 (6th Cir. 2003); Trs. of Columbia Univ. v. Roche Diagnostics GmbH, 126 F. Supp. 2d 16, 21 (D. Mass. 2000); Monsanto Co. v. Mycogen
Plant Sci., Inc., 61 F. Supp. 2d 133, 155 (D. Del. 1999); Genentech, Inc. v. Boehringer Mannheim GmbH, 989 F. Supp. 359, 364-65 (D. Mass. 1997). These
opinions were the result of a search (“gene” w/3 defin!) of the LexisNexis®
“Federal Court Cases, Combined” database.
130. Amgen, 927 F.2d at 1206.
131. Carnegie Mellon, 2007 U.S. Dist. LEXIS 20386, at *8.
132. Note that Carnegie Mellon, 148 F. Supp. 2d at 1013, simply cites Amgen for how not to define a gene.
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(“A gene is a chemical compound, albeit a complex one.”)133 is so
general as to approach the tautological, and the Carnegie Mellon University definition (“A gene may be defined as a region of
DNA that contains information that a cell uses to make a particular protein.”)134 is scientifically inaccurate (e.g., because it
ignores introns), vague, and uninformative.
In 2006, an article provocatively entitled What is a Gene?,
was published in Nature,135 a journal many—perhaps even
most—scientists would acknowledge as the most prestigious
and influential scientific journal in the world. In this article,
Helen Pearson describes widespread disagreement and confusion among biologists about the meaning of the word “gene.”136
She quotes William Gelbart, a famous and well-published geneticist at Harvard University, as saying, “I find it sometimes
very difficult to tell what someone means when they talk about
genes because we don’t share the same definition.”137 Despite
the fact that What is a Gene? was published in such a prominent journal, and has undoubtedly been read by many geneticists, this article about the uncertainty surrounding gene concepts has been cited only a single time by a U.S. patent or
patent application.138 This application cites to What is a Gene?
and states that “[w]hile the definition of a ‘gene’ is an increasingly complex issue, what is of immediate interest for drug
discovery and development is a catalogue of those genes that
encode functional, expressed proteins.”139 In other words, despite difficulties in describing what a gene actually is, the overriding priority for “drug discovery and development”140 should
be to “catalogue”141 the useful products of genes rather than the
genes that encode those useful products. This patent application may reflect a larger manifesto of biotechnology: it is more
important to locate potentially useful products of genes than to
know the characteristics of the genes that encode them. Applied

133. Amgen, 927 F.2d at 1206.
134. Carnegie Mellon, 2007 U.S. Dist. LEXIS 20386, at *8.
135. Pearson, supra note 92.
136. Id. at 399.
137. Id. at 401.
138. U.S. Patent Application Publication Number US 2007/0166765 A1, at
[0358] (filed Jan. 7, 2007) (the publication for U.S. Patent Application Serial
Number 11/653,771 (“‘771 application”)).
139. Id. (internal citation omitted).
140. Id.
141. Id.
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to gene patents, this manifesto would emphasize the description of gene function over the description of gene structure. Patent law, however, requires description of structure,142 and disallows “functional claiming” of biotechnological inventions.143
IV. GENE TALK
A. THE BIOTECHNOLOGY INDUSTRY
The biotechnology industry144 is substantially based on
geneand gene-based inventions. The products of that industry are made possible by technologies that allow genes to be
located within the genome, sequenced deoxyribonucleotide by
deoxyribonucleotide, isolated out of their original genomic loci
and spliced into brand new loci, and expressed more or less
than usual. The biotechnology industry relies on the availability of patent protection to appropriate the economic value of
genes. Patents and patent applications allow biotechnology
companies to attract investments and other sources of funding
and to protect their own immense investments in discovering,
developing, securing regulatory approval, and successfully
marketing their products. Consequently, the biotechnology industry also has strong incentives to maintain the patentability
of gene inventions. As Sheila Jasanoff has described in her
book, Designs on Nature,
[e]specially in the United States, patents played a foundational role in
the development of the biotechnology industry at several levels. First,
the extension of patents to the life sciences created new classes of
property rights in things that were previously outside the realm of
what could be owned, or even thought of as subject to ownership
claims. As a result, these objects became commodities that could have
value, be exchanged, circulate in markets, and foster productivity.
Second, much of the early development of biotechnology occurred before there were any marketable products, and patents were the only
evidence for eager venture capitalists that there might be something

142. Medical Instrumentation and Diagnostics Corp. v. Elekta AB, 344
F.3d 1205, 1211 (Fed. Cir. 2003) (“If the specification is not clear as to the
structure that the patentee intends to correspond to the claimed function, then
the patentee has not paid that price [the quid pro quo of disclosing structure
corresponding to function] but is rather attempting to claim in functional
terms unbounded by any reference to structure in the specification. Such is
impermissible under the [Patent] statute.”)
143. See, e.g., University of Rochester v. G. D. Searle, Inc., 249 F. Supp. 2d
216236 (W.D.N.Y. 2003).
144. Herein, the biotechnology industry is assumed also to include pharmaceutical companies significantly dependent on biotechnologies.
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of future value to justify present investment. Third, patents provided
some assurance to jittery investors that they would not be mired in
endless legal wrangling if commercially useful products ever came on
line. Fourth, patents proved to be a way of sorting out the competing
claims to participants in an increasingly complex web of invention
that linked together the disparate interests of patients, research subjects, farmers, academic researchers, universities, start-up firms, government, and industry.145

The patent system offers federal legal protection for gene
inventions, offering powerful rights to exclude others from
making, using, offering to sell, or selling patented genes within
the United States, or importing patented genes into the United
States.146
Patent protection for genes and their products is a keystone asset of pharmaceutical and biotechnology companies, as
well as a valuable source of revenue for universities and government research institutes. In fact, some have argued that the
main product of the biotechnology industry, which, as a whole,
has yet to turn a profit, is not genes per se, or their uses or
products, but patents claiming genes or the uses or products
thereof.147 Availability of patent protection for genes has generally been assumed to promote innovation in biotechnology,148
spurring the discovery and elucidation of relatively more new
genes, while simultaneously limiting others’ access to those
same new genes.149
B. THE RISE OF GENE TALK
Given the importance of genes to the biotechnology indus-

145. SHEILA JASANOFF, DESIGNS ON NATURE: SCIENCE AND DEMOCRACY IN
EUROPE AND THE UNITED STATES 203–04 (2005) (internal citations omitted).
146. 35 U.S.C. § 271(a) (2006).
147. See, e.g., John M. Golden, Biotechnology, Technology Policy, and Patentability: Natural Products and Invention in the American System, 50
EMORY L.J. 101, 105-06 (2001).
148. In their recent study of the role that the patent system plays in spurring innovation, James Bessen and Michael J. Meurer suggest the patent system may indeed promote innovation in the pharmaceutical/biotechnology industry. JAMES BESSEN & MICHAEL J. MEURER, PATENT FAILURE—HOW
JUDGES, BUREAUCRATS, AND LAWYERS PUT INNOVATORS AT RISK 85–88 (2008).
As Bessen and Meurer have stated, “The evidence certainly is consistent with
the notion that patents encourage American pharmaceutical R & D.” James
Bessen & Michael J. Meurer, Do Patents Stimulate R & D Investment and
Promote Growth?, PATENTLY-O BLOG (Mar. 13, 2008, 4:17 AM),
http://www.patentlyo.com/patent/2008/03/do-patents-stim.html.
149. Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The Anticommons in Biomedical Research, 280 SCIENCE 698, 699 (1998).
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try, threats to the coherence or accuracy of gene concepts, if
they were to undermine the prospect of receiving gene patents,
could threaten the biotechnology industry itself. Until recently,
the widespread perception of such threats has appeared to be
minimal. According to Keller,
[f]or almost fifty years, we lulled ourselves into believing that, in discovering the molecular basis of genetic information, we had found the
“secret of life”; we were confident that if we could only decode the
message in DNA’s sequence of nucleotides, we would understand the
“program” that makes an organism what it is. And we marveled at
how simple the answer seemed to be.150

As Francis Crick so succinctly put it, “DNA makes RNA,
RNA makes protein, and proteins make us.”151
In fact, genes have been a scientific and cultural success
story to rival any in the history of science. As Keller suggests,
[t]oday, the prominence of genes in both the general media and the
scientific press suggests that in this new science of genomics, twentieth-century genetics has achieved its apotheosis. Yet, the very successes that have so stirred our imagination have also radically undermined their core driving concept, the concept of the gene.152

Keller considers the gene to be a scientific concept whose
days of influence may be numbered, because
even though the message has yet to reach the popular press, to an increasingly large number of workers at the forefront of contemporary
research, it seems evident that the primacy of the gene as the core
explanatory concept of biological structure and function is more a feature of the twentieth century than it will be of the twenty-first. What
will take its place? Indeed, we might ask, will biology ever again be
able to offer an explanatory framework of comparable simplicity and
allure?153

However, Keller has identified several important roles that
gene talk serves in maintaining belief in the fiction of the
“gene” even in the face of mounting scientific evidence to the
contrary:
Paramount among these is the convenience of gene talk as an operational shorthand for scientists working in specific experimental contexts. Furthermore, gene talk identifies concrete levers or handles for
effecting specific kinds of change. And finally, gene talk is an undeniably powerful tool of persuasion, useful not only in promoting research agendas and securing funding but also (perhaps especially) in
marketing the products of a rapidly expanding biotech industry.154

150.
151.
152.
153.
154.

KELLER, supra note 21, at 7.
Id. at 54.
Id. at 5.
Id. at 9.
Id. at 10.
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C. GENE TALK AND GENE PATENTS
Gene talk by the biology community to constituencies outside that community rarely addresses the complexities and uncertainties surrounding genes. One explanation for such omission is the perceived need to simplify complex scientific
concepts to communicate effectively to constituencies lacking
scientific knowledge and training. The lack of consensus within
the biology community regarding gene concepts may constrain
what information can accurately and effectively be communicated. An alternative explanation is that the biologists circumscribe their disagreements about gene concepts to occur only
within their own community, while they maintain a normative
silence on those same disagreements when addressing outside
constituencies, to protect their access to valuable gene patents.
In other words, the biology community tells a story of complexity internally, whereas it tells a different, much simpler, story
externally. Such epistemic compartmentalization would help
the biology community to achieve two important goals simultaneously: (1) relatively free internal scientific enquiry about
genes to foster scientific advances and (2) minimization of external leakage of internal scientific disputes to protect continued access to potentially valuable gene patents. In fact, goal (2),
by proprietizing and monetizing the fruits of goal (1) might be
viewed by at least some in the biology community as one method of promoting goal (1).
Keller’s research supports the notion that those with
strong incentives to sustain the concept of the “gene” may engage in gene talk with the aim of sustaining the vitality of what
many geneticists now consider a moribund idea:
Throughout the many variations and transformations that we have
seen in the concept of the gene over the course of its lifetime, it had
always been possible in the past to contain whatever definitional difficulties had plagued that concept; one might even say that it had
been functional, both experimentally and professionally, to keep its
internal incoherence under wraps.155

In fact, Keller has expressly questioned whether the biology community has attempted to obscure the failure of the gene
concept from constituencies outside biology community. As she
has stated, “It’s been a growing conviction of mine that biologists have a whole other way of talking to each other in the lab
than they do to the public.”156
155. Id. at 69–70.
156. Brown, supra note 2.
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How the biology community portrays genes to the public
may have profound effects on what society believes about
genes. To understand how scientific concepts or technologies affect societies, Jasanoff has stressed the importance of also
“ask[ing] how societies produce authoritative knowledge and
functioning technological artifacts.”157 By considering the latter
question,
it has been possible to demonstrate that the products of the sciences,
both cognitive and material, embody beliefs not only about how the
world is, but also how it ought to be. . . . The apparent firmness of the
devices with which we make sense of our existence . . . is maintained
through more or less purposive action by identifiable actors. Accordingly, to understand how . . . natural entities such as “the gene”
function in the world, one has to ask how diverse actors use and understand the concept, how it is articulated through formal and informal practices, where and by whom it is contested, and how it reasserts itself in the face of challenges to its integrity or meaning.158

Gene talk fits well into this conceptual framework.
Biology is a branch of science devoted to studying especially complex structures and processes. Perhaps due in part to
this complexity, the biology community has achieved considerable success in preventing the gene concept from becoming externally contested. While gene concepts are vigorously contested within the biology community, 159 the bar for legitimacy
and authority in this debate is exceedingly high: doctoral degrees, professorships, publication in peer reviewed journals,
memberships in exclusive learned societies, and perhaps even
gene patent inventorship are required. Indeed, this high entry
barrier largely excludes those with lesser credentials from
access to these internal gene debates. Members of the biology
community already in possession of such credentials tend to
command a privileged position in external discourse about
genes. Their opinions about genes tend to be considered more
authoritative by constituencies beyond the biology community
than are opinions expressed by less credentialed actors outside
that community. Although the biology community understands
that there remain great uncertainties regarding gene concepts,
the value its members place on the prospect of receiving gene
patents, and the monetary rewards that may accompany them,
may create significant disincentives to expressing to those outside the biology community—including the USPTO—how com157. JASANOFF, supra note 145, at 19.
158. Id.
159. See, e.g., Pearson, supra note 92 at 399–401.
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plex, complicated, and uncertain gene concepts actually are.
Consequently, the biology community contests gene concepts
internally, while simultaneously portraying the gene to other
constituencies—including the USPTO—as relatively predictable and straightforward. Thus, adapting the Jasanoff rubric,
the biology community may be able to maintain “the apparent
firmness of the [gene] device[]” by its “purposive action” of promoting a simple and predictable gene to outside constituencies,160 in particular the USPTO.
Significant incentives exist for a patent applicant not to
acknowledge uncertainty or incoherence in the gene concept because such acknowledgment risks lowering the probability that
the USPTO will grant the applicant’s patent, or exposing the
patent later to invalidity challenges in litigation. Widespread
acknowledgment of this uncertainty or incoherence would have
the potential to undermine the market value of the biotechnology industry, as well as to impoverish other beneficiaries of
gene patents, such as investors, universities, and patent attorneys and agents. Patent applicants have an affirmative obligation to disclose certain information to the USPTO.161 Such
“[i]nformation must be disclosed [by a patent applicant] when it
is material to patentability [of a patent application].”162 The reluctance to admit uncertainties in gene concepts certainly violates the spirit of this affirmative obligation of disclosure; and,
depending upon the context, it could also violate the letter of
this obligation. If a patent applicant claiming a gene or generelated invention were aware of a prior art reference whose
teaching cast into doubt the validity of the claimed invention or
the sufficiency of the disclosure supporting the claimed invention, the patent applicant would be obligated to provide that
prior art reference to the USPTO even if this lowered the probability of the claim ever issuing. Much prior art exists detailing
the many uncertainties that surround genes, gene structures,
and gene functions.163 Yet, such prior art is rarely included in
the patent specifications of gene patents. Even in litigation,
gene patents rarely fact the issue of gene concepts in more than

160. JASANOFF, supra note 145, at 19.
161. 37 C.F.R. §1.56 (2008).
162. Critikon, Inc. v. Becton Dickinson Vascular Access, Inc., 120 F.3d
1253, 1257 (Fed. Cir. 1997).
163. See, e.g., Pearson, supra note 92, at 399–401 (citing studies and the
general consensus within the biology community that our understanding of
‘gene’ is not completely accurate).
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a cursory manner, despite the fact that uncertainty about gene
concepts may have the potential to cast doubt on the validity of
many gene patents. Gene concepts rarely arise in patent litigation, which may be evidence that gene talk has successfully influenced even the judicial process.164
Jasanoff has suggested that the economic success, and
even existence, of the biotechnology industry is undergirded by
the availability of gene patents.”165 In her view, the patent system serves a variety of functions as it mediates between “inventors” of genes (and other biotechnological inventions) and markets capable of imbuing genes with economic value.166 Patents
play many valuable roles in support of the biotechnology industry, and confer considerable economic value on the beneficiaries
of gene, and gene-based, inventions. Consequently, it would be
rational for beneficiaries of the patent system to support the
continuing availability of patent protection for gene, and genebased, inventions by engaging in gene talk.
The acceptance by the patent system of a gene concept that
is inaccurately simplified and predictable might even influence
gene concepts in the reverse direction as well. The “patent gene
concept” might influence biologists to describe, and even think
about, genes in a manner consistent with patent availability.
The prospect of a patent-derived windfall is ever-present
among biologists, especially those involved in medical research.
Although there may be other rewards for pursuing biology,
such as Mertonian norms of free enquiry and free exchange of
ideas, prestige, intellectual challenge, and a sense of importance to society, the possibility of winning the patent-lottery by
patenting a lucrative gene may be a significant incentive not to
undermine the patentability of genes, even at the expense of
debate within the biology community. The biology community
may thus possess an incentive to privilege a simple and uncomplicated gene concept not only to the outside world, but also
within its own intellectual community, instead of promoting
debate about competing gene concepts, or what, if anything, a
gene actually is. In short, the “patent gene concept” may also
influence how biologists portray and conceive of genes, encouraging them, for example, to emphasize the certainty of knowledge about the gene over the uncertainty.

164. See supra note 129 and related discussion.
165. JASANOFF, supra note 145, at 203–04.
166. Id.
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Biologists and the biotechnology industry may have good
reason to avoid publicly trumpeting the failure of the gene concept in public. Although the USPTO does consider genes per
seat least when isolated or purifiedto be patentable subject
matter, it has excluded fragments of genes from patentability.167 In the early 1990s, the USPTO began to reject patent applications claiming expressed sequence tags (“ESTs”).168
As defined by the Court of Appeals for the Federal Circuit,
“[a]n EST is a short nucleotide sequence that represents a
fragment of a cDNA clone.”169 In In re Fisher, the Court rejected the patentability of such gene fragments as lacking utility (and enablement) “because Fisher does not identify the function for the underlying protein-encoding genes.”170 If claims to
ESTs tend to lack utility and enablement, then so might claims
to genes composed of multiple gene fragments. Gene talk can
contribute to the solution to this problem by avoiding discussion of the complexities of gene structure, and focusing, instead, on a simple and comfortable, though inaccurate, gene definition.
An influential gene patent case, Amgen v. Chugai Pharmaceutical Co., 927 F.2d 1200, 1206 (Fed. Cir. 1991), may provide
additional incentive for biologists and those in the biotechnology industry to engage in protective gene talk. Amgen mandates
a significant level of detailed knowledge about a gene before a
patent claiming the gene can be granted:
A gene is a chemical compound, albeit a complex one, and it is well established in our law that conception of a chemical compound requires
that the inventor be able to define it so as to distinguish it from other
materials, and to describe how to obtain it. Conception does not occur
unless one has a mental picture of the structure of the chemical, or is
able to define it by its method of preparation, its physical or chemical
properties, or whatever characteristics sufficiently distinguish it. It is
not sufficient to define it solely by its principal biological property,
e.g., encoding human erythropoietin, because an alleged conception
having no more specificity than that is simply a wish to know the
identity of any material with that biological property. We hold that
when an inventor is unable to envision the detailed constitution of a
gene so as to distinguish it from other materials, as well as a method
for obtaining it, conception has not been achieved until reduction to

167. In re Fisher, 421 F.3d 1365, 1373 (Fed. Cir. 2005).
168. See Leslie Roberts, Gene Patents: Rumors Fly over Rejection of NIH
Claim, 257 SCIENCE 1855, 1855 (1992) (noting that the USPTO rejected NIH’s
EST application in an office action dated August 20, 1992).
169. In re Fisher, 421 F.3d at 1367.
170. Id at 1376.
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practice has occurred, i.e., until after the gene has been isolated.171

Without gene talk, the standard of description mandated
by Amgen might be insurmountable for many gene patent applicants. In light of the current understanding of how difficult
it is to define a eukaryotic gene, the standard articulated by the
court may be unreachable. Patent applicants might be able to
isolate mRNA molecules and then reverse transcribe them into
cDNAs. However, successfully envisioning “the detailed constitution of a gene” has the potential to become an ever more difficult challenge if gene concepts continue to decay and degrade.
Again, gene talk may provide a degree of prophylaxis.
For example, as a consequence of how genes tend to be
claimed in patents, the perception may already have grown
among biologists that “genes” are synonymous with nucleic acid
sequences. The patenting of gene-associated DNA sequences
may have altered the perception among both biologists and the
public regarding what is, and is not, a gene. Gene talk may
even create an incentive among biologists for duplicity; it may
encourage them to depict genes inconsistently in scientific publications and patent applications. Differing portrayals of the
same gene in related publications and patent applications
might encourage patent examiners to doubt the sincerity of
gene definitions in patent applications. In addition, such behavior might qualify as inequitable conduct, rendering relevant
patents unenforceable.172
Not every aspect of genes has been beyond public contention. Indeed, the biology community appears to have failed to
persuade the public that patenting genes is socially valuable; in
this sense, the gene concept promoted by the biology community has failed to become a generally authoritative view among
constituencies outside the biology community. As Jasanoff describes,
[t]he political controversies surrounding the patenting of DNA sequences in the United States raises [sic] an interesting puzzle. Why
did concern surface with regard to these products when equally significant enlargements in the scope of patentability—from nonliving to
living matter and from lower to higher organisms—had garnered
nothing but praise from U.S. scientists? We must conclude that this

171. Amgen, 927 F.2d at 1206 (citation omitted).
172. Critikon, Inc. v. Becton Dickinson Vascular Access, Inc., 120 F.3d
1253, 1256 (Fed. Cir. 1997) (“Inequitable conduct resides in the failure to disclose material information with an intent to deceive or mislead the PTO.”) (citing J.P. Stevens & Co. v. Lex Tex, Ltd., 747 F.2d 1553, 1559–60 (Fed. Cir.
1984)).
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step more than any previous one created competitive divisions within
the very heart of biotechnological research and development.173

Yet, even where the gene patent issue has become contentious, it has been concerns over ethics, morality, and free access
to genes for research purposes—not any perceived ambiguities
or complexities of the gene concept—that have animated the
debate. For example, in the vigorous debate surrounding proposed H.R. 977 (“A bill to amend title 35, United States Code,
to prohibit the patenting of human genetic material”), little
support exists in the legislative history for the proposition that
genes should be unpatentable because the gene concept is inaccurate.174 Despite the influence public acknowledgement of uncertainties surrounding the gene concept might have had on
the debate, it is possible that gene talk successfully influenced
members of the biology community not to share their internal
controversies and debates with outside constituencies that
could have interfered with the prospect of receiving valuable
gene patents.
V. CONCLUSION
The concept of the gene has evolved rapidly over the last
one-hundred years. At various times, gene concepts have emphasized materiality, agency, reproductive capacity, and the
ability to direct cells and organisms.175 In the words of Erwin
Schrodinger, the gene is “lawcode and executive power—
architect’s plan and builder’s craft—in one.”176
Methods of isolating, manipulating, sequencing, and controlling genes formed the foundations of the biotechnology in-

173. JASANOFF, supra note 145, at 224.
174. Genomic Research and Accessibility Act, H.R. 977, 110th Cong. (2007);
see, e.g., Legislation to Prohibit Human Genetic Patents Proposed in U.S., PHG
FOUND., Feb. 12, 2005, http://www.phgfoundation.org/news/3148 (pointing out
concern that gene patents hinder scientific research); Bill Seeks to Ban Gene
Patents (National Public Radio radio broadcast Mar. 2, 2007), available at
www.npr.org/templates/story/story.php?storyId=7689495 (discussing the implications of gene patenting with Stanford Law Professor Robin Feldman, but
not discussing potential problems with the gene concept); Sheppard Mullin,
Bill to Prohibit Patents on Nucleic Acid Sequences Presented to U.S. House of
Representatives, INTELLECTUAL PROPERTY LAW BLOG (June 21, 2007),
http://www.intellectualpropertylawblog.com/archives/patents-bill-to-prohibitpatents-on-nucleic-acid-sequences-presented-to-us-house-ofrepresentatives.html (discussing motivating factors behind bill, but not mentioning insufficiencies in gene concept.
175. KELLER, supra note 21, at 47 (citations omitted).
176. Id.
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dustry. Gene patents contributed to the growth of the biotechnology industry into a huge and valuable component of the
modern economy.
However, the concept of the gene has increasingly been in
jeopardy since at least the discovery of introns in the late
1970s. Regardless of the complexity, predictability, definability,
or even the actual existence of the gene, gene talk has been,
and remains, a powerful form of persuasion. The biology community has relied on vigorous internal debates about gene concepts continually to push back the frontiers of genetics, while
the same community has simultaneously used gene talk authoritatively to portray the gene to external constituencies as uncontroversial and relatively simple. Patent applicants, who are
typically members of the biology community, also appear to
have employed gene talk to assist them in securing patent
rights in their gene, or gene-based, inventions.
Gene talk about the particulate materiality and simple
predictability of genes may even have subverted the view that
members of the biology community have of genes by creating an
incentive for patent applicants to view the process of patenting
genes—a process rich in institutional and governmental legitimacy—as making the object of a patent—the gene—more substantial and real. Based on the failure of structural concepts of
the gene, functional claiming of genes might seem a more fruitful strategy for applicants seeking to patent genes. However,
the success of gene talk may have retarded this development.
Gene talk may be a powerful mode of communication and
persuasion. It appears to have maintained the view of genes as
simple and predictable enough to be patentable long after the
biology community broadly lost faith in a single, objective, and
relatively uncomplicated gene concept. Thus, gene talk has preserved the prospect of gene patents and their attendant monetary rewards. Given the powerful results of, and the vast authority achieved by, gene talk, it may take much longer to fade
in influence than the concept of the gene itself.

